# Semaglutide Effects, Side Effects, and Safety: What the Record Shows > Semaglutide effects and side effects: what people report (anecdotal) plus the cited safety cautions from clinical trials and pharmacovigilance. No dosing advice — a literature and community digest. Reported benefits and downsides, clearly labeled, alongside cited cautions from the trial and pharmacovigilance record. ## Start here This page is about the Semaglutide effects people actually experience — the good and the bad — and the safety facts the published research has established. It is split into two clearly separated parts. The first part is what people report: helpful for context, but it is anecdotal and has not been measured in a controlled trial, so treat it as stories, not proof. The second part is the safety section, where every caution is tied to a study you can look up. In plain terms: most people who take semaglutide report eating much less and losing weight, and the most common complaint by far is stomach upset, especially nausea in the first weeks and after each dose increase. Some side effects, like hair shedding, are most likely caused by losing weight quickly rather than by the drug itself. None of this is medical advice, and no doses are given here. For the dosing schedules used in studies, see the [dosage research context](/dosage). ## What people report These are effects described by people using semaglutide and discussed in patient communities — **anecdotal, not clinical evidence**, and not verified by controlled trials. They are summarized here for context only. No doses are attached, and nothing below should be read as a finding. **Benefits people describe** - **Appetite suppression and quieter "food noise"** (frequently reported). The most common benefit people describe is that the constant background chatter about food goes quiet, often within the first week or two. Many say they feel full faster, eat a third to a half of their old portions, and stop obsessing over the next meal — several call it the single most life-changing effect. - **Reduced cravings** (frequently reported). People repeatedly report that sweet-tooth and sugar cravings drop sharply, and that fried, greasy, and high-fat foods stop appealing — sometimes turning slightly off-putting. Several describe naturally drifting toward fruit, vegetables, and lighter meals. - **Weight loss** (frequently reported). The large majority of reviewers report losing weight, often described as steady and substantial over several months, with the pace slowing after the early period. Many tie it directly to eating much less. - **Better blood-sugar control** (commonly reported). Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with some describing fasting numbers dropping into normal ranges and steadier daytime energy. - **Reduced desire to drink alcohol** (occasionally reported). A recurring secondary observation is that the urge to drink fades along with food cravings; some say they simply lose interest in drinking. ## Semaglutide side effects people report Still **anecdotal, not clinical evidence** — these are community reports of semaglutide side effects, grouped plainly. They overlap with, but are not the same as, the trial-measured adverse effects in the safety section below. - **Nausea, sometimes with vomiting** (frequently reported). The single most reported side effect, mentioned by roughly a third of reviewers; a subset escalates to vomiting at its worst. It tends to peak in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. Many manage it with smaller, lighter meals and plenty of water. - **Sulfur or "egg" burps** (commonly reported). Foul-smelling burps people compare to rotten eggs or sulfur, often after a dose increase, sometimes lasting hours or weeks, frequently with bloating and a sense of food sitting too long. - **Bowel changes** (commonly reported). Both constipation and diarrhea, sometimes alternating. Constipation shows up as hard, infrequent stools; diarrhea is often worse in the days right after a dose or after rich food. Some note the constipation partly reflects eating very little. - **Acid reflux and heartburn** (occasionally reported), often alongside burping and bloating, tracking with dose increases. - **Fatigue early on** (commonly reported), especially in the day or two after each injection and during the first weeks, usually easing with time. - **Food aversions, taste changes, and over-suppressed appetite** (occasionally reported) — active aversions to fatty or meaty foods, a metallic taste, heightened smell sensitivity likened to morning sickness, and for a few, appetite suppression so strong they must remind themselves to eat. - **Hair shedding and facial gauntness** (sometimes reported), usually noticed a few months in and widely attributed by users to rapid weight loss rather than the drug; the shedding is generally described as temporary. - **Headaches and dizziness** (occasionally reported), often in the first days of a new dose and linked to under-hydration or eating too little. - **Injection-site reactions** (sometimes reported) — minor, short-lived redness, itching, a small bump, or tenderness. ## Safety and cautions This section is the cited counterpart to the reports above. Each caution below is grounded in the trial, review, or pharmacovigilance literature and is referenced by number. This is where the genuinely useful context lives. **Gastrointestinal intolerance, especially during dose escalation.** Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects in clinical trials and the leading cause of stopping treatment. In a pooled analysis of the STEP weight-management program these events were predominantly mild-to-moderate and transient, concentrated around the titration period [16]; a dedicated safety review reported nausea in roughly one-third of patients [5], and real-world pharmacovigilance reporting is likewise dominated by gastrointestinal events [17]. This is clinical, not theoretical: the slowing of gastric emptying that underlies it is part of how the drug works. **Medullary thyroid carcinoma history (boxed warning).** GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors derived from rodent studies, in which such tumors occurred at supratherapeutic exposures [18]. A dedicated assessment concluded that available human data do not establish a clear increase in thyroid cancer attributable to semaglutide, so the signal should be framed as unconfirmed in humans [18]; nevertheless, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the rodent finding [5]. **Acute pancreatitis (class warning).** Acute pancreatitis is a recognized class warning for GLP-1 receptor agonists, and treatment is conventionally stopped if it is suspected. A dedicated safety review notes that pancreatic-cancer signals remain ones for which definitive conclusions cannot yet be drawn owing to low incidence, rather than confirmed associations [5]. This caution is precautionary, not a demonstrated quantitative risk increase. ## Further safety cautions **Gallbladder and biliary disease.** A dedicated safety review found an increased risk of biliary disease (gallstones) with semaglutide, attributed largely to the rate and magnitude of weight loss rather than a direct drug toxicity — but the increase versus placebo is a real trial and pharmacovigilance finding, not merely theoretical [5]. **Pre-existing diabetic retinopathy with rapid glycemic correction.** In SUSTAIN-6, rates of diabetic-retinopathy complications were significantly higher with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated among patients with pre-existing retinopathy whose blood sugar was lowered rapidly [2]. The leading interpretation is early worsening driven by the speed of correction rather than a direct retinal toxicity; monitoring is advised when glycemia is corrected quickly [5]. **Loss of lean (muscle) mass.** A STEP-program DXA body-composition substudy reported that the weight lost comprised both fat mass and a meaningful proportion of lean mass [9]. Because rapid, large-magnitude weight loss can erode muscle, this raises a sarcopenia concern (particularly in older adults) and has motivated research into protein intake and resistance training. The lean-mass loss is an observed trial finding; the downstream sarcopenia risk is a mechanistically reasoned extrapolation. **Weight regain after stopping.** In the STEP 1 trial extension, participants regained a mean of roughly 11.6 percentage points of body weight within one year of stopping, and cardiometabolic improvements reverted toward baseline [19]; the STEP 4 randomized-withdrawal design likewise showed regain after switching to placebo [20]. This frames obesity pharmacotherapy as a chronic, not curative, intervention. **Hair shedding (telogen effluvium) with rapid weight loss.** A pharmacovigilance disproportionality analysis identified a reporting signal for alopecia with semaglutide and tirzepatide [21], and a separate dermatology study linked telogen effluvium — a reversible diffuse shedding — to the magnitude and rate of weight loss [22]. The signal is most consistent with rapid-weight-loss-associated shedding rather than direct drug toxicity. **Pregnancy (contraindicated).** Semaglutide is contraindicated in pregnancy per approved labeling. Because the elimination half-life is about one week, with effectively complete clearance only about five weeks after the last dose, label guidance advises stopping well in advance of a planned pregnancy (commonly cited as roughly two months) [15]. **Narrow-therapeutic-index oral drugs during titration.** A systematic review of drug interactions between GLP-1 receptor agonists and oral medications found that the delayed gastric emptying these agents produce generally does not cause clinically significant interactions, but advised caution and monitoring for narrow-therapeutic-index oral drugs, especially during dose escalation [14]. ## Then and now Semaglutide is the product of Novo Nordisk's incretin-peptide chemistry, built on the company's earlier GLP-1 analogue and engineered for once-weekly dosing through DPP-4 resistance and albumin-binding fatty-acid acylation [15]. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily formulation following in 2019-2020 and a chronic weight-management indication in 2021. Its cardiovascular-outcomes evidence (SELECT) read out in 2023 [3] and its kidney-outcomes evidence (FLOW) in 2024 [6], with the corresponding risk-reduction and chronic-kidney-disease indications approved in 2024 and 2025; a metabolic dysfunction-associated steatohepatitis (a serious fatty-liver disease) indication followed in 2025 on the strength of the ESSENCE trial [24]. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce semaglutide; that pathway was curtailed once the shortage was declared resolved in early 2025. --- A documentation-grade reading of the semaglutide literature, indexed by half-life and dose; not a clinic, not a pharmacy, and nothing here prescribed or dispensed.